The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai APACTRON Particle Equipment Co., Ltd for marketing as an innovative product. This marks a significant milestone as it is the first proton therapy system developed in China, supported by the Ministry of Science and Technology during the “13th Five-Year Plan” period.
System Overview and Components
The proton therapy system consists of an accelerator system and a treatment system. The accelerator system includes an injector system, a low-energy transmission system, a main accelerator system, a high-energy beam transmission system, and an auxiliary electrical system. The treatment system comprises a fixed beam treatment system, a 180° rotating beam treatment system, and a treatment planning system.
Clinical Benefits and Applications
The product provides proton beam radiation therapy, which is designed to achieve high dose delivery at the tumor site while reducing the dose to surrounding normal tissue, particularly the tissue behind the target area. This advanced therapy is suitable for the treatment of systemic solid malignant tumors and certain benign diseases, offering a more precise and targeted approach to cancer treatment.
Future Outlook
The approval of Shanghai APACTRON’s proton therapy system by the NMPA highlights China’s progress in developing advanced medical technologies. This innovative system is expected to enhance the treatment options available for patients with solid tumors and other conditions, contributing to improved clinical outcomes and patient care.-Fineline Info & Tech
